EFFECTIVENESS OF TUBERCULOUS RECOMBINANT ALLERGEN SKIN TESTS FOR DETECTING TUBERCULOSIS IN CHILDREN AND ADOLESCENTS OF MOSCOW IN 2013

Explanation. Mantoux test is used to detect the tuberculous infection; however, low specificity of this method results in a high rate of false positive responses due to cross-reactions of PPD (protein purified derivate) antigens contained in many mycobacterial species and Bacillus Calmette-Guerin (BCG) strains. New drug Diaskintest (DST) — recombinant protein CFP10-ESAT6 produced by Escherichia coli BL21(DE3)/pCFP-ESAT proved to be the best acceptable diagnostic drug. The article was aimed at studying effectiveness of tuberculous recombinant allergen tests for detecting tuberculosis in the children and adolescents, who were registered in Moscow in 2013. Methods. Mantoux tests were used to examine 1,420,100 persons; positive reactions were observed in 1,020,000 children and adolescents (71,8%); 131,361 (12.9%) of them were examined using DSTs. Results. Positive reactions to DST were observed in 3,304 persons (2.5% of the persons with positive reactions to Mantoux test). The tuberculosis detection rate among the persons with positive reactions to Mantoux tests using 2TU PPD-L (Leningrad Research Institute of Vaccines and Serums) is 0.13%, among the persons with positive reactions to DSTs — 4.9%, i.e. 40 times more often (p = 0.000). Post-tuberculosis alterations were detected in 169 persons: in 0.13% of the persons with positive reactions to Mantoux tests using 2TU PPD-L and in 5.1% of the persons with positive reactions to DSTs (p = 0.000). Conclusion. Cohort studies conducted in Moscow demonstrated high effectiveness of Diaskintests for detecting tuberculosis in children and adolescents. High sensitivity of the method helps to detect the overwhelming majority of the persons with tuberculosis.

tuberculosis, tuberculous recombinant allergen skin test, diagnosis, tuberculosis in children and adolescents, new skin test, sensitivity, specificity

1. Lein A., von Reyn C., Ravn P. et al. Cellular immune responses to ESAT-6 discriminate between patients with pulmonary disease due to Mycobacterium avium complex and those with pulmonary disease due to Mycobacterium tuberculosis. Clin Diagn Lab Immunol. 1999; 6: 606–609.

2. Mahairas G., Sabo P., Hickey M. et al. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol. 1996; 178: 1274–1282.

3. Andersen P., Doherty T., Pai M., Weldingh K. The prognosis of latent tuberculosis: can disease be predicted? Trends Mol Med. 2007; 13 (5): 175−182.

4. Ewer K., Deeks J., Alvarez L. et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet. 2003; 361: 1168–1173.

5. Arend S., Thijsen S., Leyten E. et al. Comparison of two interferon-gamma assays and tuberculin skin test for tracing tuberculosis contacts. Am J Respir Crit Care Med. 2007; 175 (6): 618−627.

6. Menzies D., Pai M., Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med. 2007; 146: 340–354.

7. Mack U., Migliori G., Sester M. et al. LTBI: latent tuberculosis infection or lasting immune responses to Mycobacterium tuberculosis? A TBNET consensus statement. Eur Respir J. 2009; 33: 956–973.

8. Pai M., Zwerling A., Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008; 149 (3): 177–184.

9. Andersen P., Andersen A., Sorensen A., Nagai S. Recall of long-lived immunity to Mycobacterium tuberculosis infection in mice. J Immunol. 1995; 154 (7): 3359−72.

10. Vordermeier H., Chambers M., Cockle P. et al. Correlation of ESAT-6-specific gamma interferon production with pathology in cattle following Mycobacterium bovis BCG vaccination against experimental bovine tuberculosis. Infect Immun. 2002; 70: 3026–3032.

11. Dietrich J., Aagaard C., Leah R. et al. Exchanging ESAT6 with ТВ 10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol. 2005; 174: 6332−6339.

12. Bakir M., Millington K., Soysal A. et al. Prognostic value of a T-cell-based, interferon-γ biomarker in children with tuberculosis contact. Ann Intern Med. 2008; 149: 777–787.

13. Diel R., Loddenkemper R., Meywald-Walter K. et al. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med. 2008; 177 (10): 1164–1170.

14. Doherty T., Demissie A., Olobo J. et al. Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J Clin Microbiol. 2002; 40 (2): 704–706.

15. Lienhardt C., Fielding K., Hane A. et al. Evaluation of the Prognostic Value of IFN-γ Release Assay and Tuberculin Skin Test in Household Contacts of Infectious Tuberculosis Cases in Senegal. PLoS ONE. 2010; 5 (5): e10508. Doi:10.1371/journal.pone.0010508.

16. Mazurek G., Weis S., Moonan P. et al. Prospective comparison of the tuberculin skin test and two whole-blood interferon-gamma release assays in persons with suspected tuberculosis. Clin Infect Dis. 2007; 45: 837−845.

17. Diel R., Nienhaus A., Schaberg T. Cost-effectiveness of isoniazid chemoprevention in close contacts. Eur Respir J. 2005; 26: 465–473.

18. Dosanjh D., Hinks T., Innes J. et al. Improved diagnostic evaluation of suspected tuber-culosis. Ann Intern Med. 2008; 148: 325–336.

19. Goletti D., Stefania C., Butera O. et al. Accuracy of immunodiagnostic tests for active tuberculosis using single and combined results: a multicenter TBNET Study. PLoS ONE. 2008; 3: e3417.

20. Brandli O., Desgrandchamps D., Gabathuler U. et al. Manual of Tuberculosis. Bern, Swiss Lung League. 2007. Available at: www.lung.ch

21. National Institute for Health and Clinical Excellence. Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for its Prevention and Control. London, National Institute for Health and Clinical Excellence. 2006. Available at: www.nice.org.uk.

22. The National Collaborating Centre for Chronic Conditions. Tuberculosis. Clinical Diag-nosis and Management of Tuberculosis, and Measures for its Prevention and Control. London, Royal College of Physicians. 2006.

23. Borisov S.E., Lukina G.V., Slogotskaya L.V., Kochetkov Ya.A., Guntupova L.D. Kulikovskaya N.V. Screening and monitoring of tuberculosis infection in rheumatic patients receiving genetically engineered biological agents. Tuberkulez i bolezni legkikh = Tuberculosis and Lung Diseases. 2011; 6: 42−50.

24. Mazurek G., Jereb J., Lobue P. et al. Guidelines for using the Quanti FERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep. 2005; 54: 49–55.

25. Kiselev V.I., Baranovskii P.M., Pupyshev S.A. et al. A new skin test for the diagnosis of tuberculosis based on recombinant protein ESAT-CFP. Molekulyarnaya meditsina = Molecular medicine. 2008; 4: 4–6.

26. Lalvani A., Millington K.A. T cell-based diagnosis of childhood tuberculosis infection. Curr Opin Infect Dis. 2007; 20: 264–271.

27. Lalvani A. Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy. Chest. 2007; 131: 1898–1906.

28. Mori T., Sakatani M., Yamagishi F. et al. Specific detection of tuberculosis infection: an interferon-c-based assay using new antigens. Am J Respir Crit Care Med. 2004; 170: 59–64.

29. Pai M., Kalantri S., Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: part I. Latent tuberculosis. Expert Rev Mol Diagn. 2006; 6: 413–422.

30. Richeldi L., Ewer K., Losi M. et al. Early diagnosis of subclinical multidrug-resistant tu-berculosis. Ann Intern Med. 2004; 140: 709–713.

31. Slogotskaya L.V., Senchikhina O.Yu., Bogorodskaya E.M. The sensitivity of the test with the allergen tubercular recombinant protein containing ESAT6-CFP10, in new TB cases of children and adolescents in Moscow. Tuberkulez i sotsial'no znachimye zabolevaniya = Tuberculosis and socially important diseases. 2013; 1: 37−44.